dr. perl on the outlook of flt3 inhibitors for aml
Published 6 years ago • 217 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
9:39
alexander perl, md: the new flt3 inhibitor gilteritinib is “well-tolerated” in aml
-
1:27
dr. perl on choosing the optimal therapy in aml
-
5:49
emerging flt3 inhibitors in aml
-
2:38
dr. erba on flt3 inhibitors for the treatment of aml
-
4:18
second-generation flt3 inhibitors in aml: quizartinib
-
4:05
optimizing use of flt3 inhibitor therapy for aml
-
1:40
alexander perl, md, discusses treatment options for patients with flt3-itd positive aml
-
1:44
dr. perl on evolving treatment in aml
-
0:58
alexander perl, md, discusses the importance of sustained inhibition when selecting a flt3 inhibitor
-
1:32
novel treatment combinations for flt3-mutated aml
-
7:16
second-generation flt3 inhibitors for aml
-
1:18
dr. levis discusses the ideal use of quizartinib in flt3-itd aml
-
1:18
alexander perl, md, on flt3 inhibitors in development and importance of hitting the flt3 target
-
0:49
treatment avenues for patients with r/r flt3-mutated aml: optimizing flt3 inhibitors
-
1:25
alexander perl, md, on importance of flt3 and provides his perspective on inhibitor differences
-
3:27
novel flt3 inhibitors for aml
-
2:35
quizartinib for frontline flt3-itd aml: updated results from the quantum-first trial
-
4:05
long-term challenges with flt3 inhibition in aml
-
1:50
mark levis, md, on why the flt3 target is important in aml